Casein derived peptides and uses thereof
AssigneeChay 13 Medical Research Group N.V.
InventorZvi Sidelman
Life of this patent
Estimating the term…
Abstract
Biologically active peptides that are derived from or are similar to sequences identical with the N-terminus of the αS1 fraction of milk casein. These peptides are capable of stimulating and enhancing immune response, protecting against viral infection, normalizing serum cholesterol levels, and stimulating hematopoiesis. The casein-derived peptides are non-toxic and can be used to treat and prevent immune pathologies, hypercholesterolemia, hematological disorders and viral-related diseases, alone or in combination with other peptides or blood cell stimulating factors.
Claims164
A method of preventing or treating an autoimmune or infectious disease or condition, the method comprising administering to a subject in need thereof a therapeutically effective amount of a peptide derived from the N-terminus portion of αS1 casein.
A method of preventing or treating a blood disease or condition, the method comprising administering to a subject in need thereof a therapeutically effective amount of a peptide derived from the N terminus portion of αS1 casein.
A method of modulating blood cell formation, the method comprising administering to a subject in need thereof a therapeutically effective amount of a peptide derived from the N terminus portion of αS1 casein.
A method of enhancing peripheral stem cell mobilization, the method comprising administering to a subject in need thereof a therapeutically effective amount of a peptide derived from an N terminus portion of αS1 casein.
A method of preventing or treating a metabolic disease or condition, the method comprising administering to a subject in need thereof a therapeutically effective amount of a peptide derived from the N terminus portion of αS1 casein.
A method of preventing or treating conditions associated with myeloablative doses of chemoradiotherapy supported by autologous bone marrow or peripheral blood stem cell transplantation (ASCT) or allogeneic bone marrow transplantation (BMT), the method comprising administering to a subject in need thereof a therapeutically effective amount of a peptide derived from the N terminus portion of αS1 casein.
A method of augmenting the effect of a blood cell stimulating factor, the method comprising administering to a subject in need thereof a therapeutically effective amount of a peptide derived from the N terminus portion of αS1 casein.
A method of enhancing colonization of donated blood stem cells in a myeloablated recipient, the method comprising treating a donor of said donated blood stem cells with a therapeutically effective amount of peptide derived from the N terminus portion of αS1 casein prior to donation and implanting the donated blood stem cells in the recipient.
A method of enhancing colonization of donated blood stem cells in a myeloablated recipient, the method comprising treating said donated blood stem cells with a therapeutically effective amount of peptide derived from the N terminus portion of αS1 casein prior to implanting the donated blood stem cells in the recipient.
A method of enhancing colonization of blood stem cells in a myeloablated recipient, the method comprising treating said blood stem cells with a peptide derived from the N terminus portion of αS1 casein prior to implanting the blood stem cells in the recipient.
A method for preventing or treating a condition associated with a SARS infective agent, the method comprising administering to a subject in need thereof a therapeutically effective amount of a peptide derived from the N terminus portion of αS1 casein.
A method for preventing or treating a bacterial disease or condition, the method comprising administering to a subject in need thereof a therapeutically effective amount of a peptide derived from the N terminus portion of αS1 casein.
A pharmaceutical composition for preventing or treating an autoimmune or infectious disease or condition, the pharmaceutical composition comprising, as an active ingredient, a peptide derived from the N terminus portion of αS1 casein and a pharmaceutically acceptable carrier.
A pharmaceutical composition for preventing or treating a blood disease or condition, the pharmaceutical composition comprising, as an active ingredient, a peptide derived from the N terminus portion of αS1 casein and a pharmaceutically acceptable carrier.
A pharmaceutical composition for modulating blood cell formation, the pharmaceutical composition comprising, as an active ingredient, a peptide derived from the N terminus portion of αS1 casein and a pharmaceutically acceptable carrier.
A pharmaceutical composition for enhancing peripheral stem cell mobilization, the pharmaceutical composition comprising, as an active ingredient, a therapeutically effective amount of a peptide derived from the N terminus portion of αS1 casein and a pharmaceutically acceptable carrier.
A pharmaceutical composition for preventing or treating a metabolic disease or condition, the pharmaceutical composition comprising, as an active ingredient, a peptide derived from the N terminus portion of αS1 casein and a pharmaceutically acceptable carrier.
A pharmaceutical composition for preventing or treating conditions associated with myeloablative doses of chemoradiotherapy supported by autologous bone marrow or peripheral blood stem cell transplantation (ASCT) or allogeneic bone marrow transplantation (BMT), the pharmaceutical composition comprising, as an active ingredient, a peptide derived from the N terminus portion of αS1 casein and a pharmaceutically acceptable carrier.
A pharmaceutical composition for augmenting the effect of a blood cell stimulating factor, the pharmaceutical composition comprising, as an active ingredient, a peptide derived from the N terminus portion of αS1 casein and a pharmaceutically acceptable carrier.
A pharmaceutical composition for enhancing colonization of donated blood stem cells in a myeloablated recipient, the pharmaceutical composition comprising, as active ingredients, a peptide derived from the N terminus portion of αS1 casein and a pharmaceutically acceptable carrier.
A pharmaceutical composition for enhancing colonization of blood stem cells in a myeloablated recipient, the pharmaceutical composition comprising as active ingredients, a peptide derived from the N terminus portion of αS1 casein and a pharmaceutically acceptable carrier.
A pharmaceutical composition for treating or preventing an indication selected from the group consisting of autoimmune disease or condition, viral disease, viral infection, hematological disease, hematological deficiencies, thrombocytopenia, pancytopenia, granulocytopenia, hyperlipidemia, hypercholesterolemia, glucosuria, hyperglycemia, diabetes, AIDS, HIV-1, helper T-cell disorders, dendrite cell deficiencies, macrophage deficiencies, hematopoietic stem cell disorders including platelet, lymphocyte, plasma cell and neutrophil disorders, pre-leukemic conditions, leukemic conditions, immune system disorders resulting from chemotherapy or radiation therapy, human immune system disorders resulting from treatment of diseases of immune deficiency and bacterial infections, the pharmaceutical composition comprising, as an active ingredient, a peptide derived from the N terminus portion of αS1 casein and a pharmaceutically acceptable carrier.
A pharmaceutical composition for treating or preventing an indication selected from the group consisting of hematological disease, hematological deficiencies, thrombocytopenia, pancytopenia, granulocytopenia, dendrite cell deficiencies, macrophage deficiencies, hematopoietic stem cell disorders including platelet, lymphocyte, plasma cell and neutrophil disorders, pre-leukemic conditions, leukemic conditions, myelodysplastic syndrome, non-myeloid malignancies, aplastic anemia and bone marrow insufficiency, the pharmaceutical composition comprising, as active ingredients, a blood cell stimulating factor and a peptide derived from the N terminus portion of αS1 casein and a pharmaceutically acceptable carrier.
A purified peptide having an amino acid sequence selected from the group consisting of SEQ ID NOS:
- 1-25.
A pharmaceutical composition comprising a purified peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 1-25 and a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising a blood cell stimulating factor, said blood cell stimulating factor selected from the group consisting of thrombopoietin, erythropoietin and granulocyte colony stimulating factor (G-CSF), in combination with a purified peptide having an amino acid sequence selected from the group consisting of SEQ ID NOS:
- 1-25 and a pharmaceutically acceptable carrier.
A pharmaceutical composition for preventing or treating a condition associated with a SARS infective agent, the pharmaceutical composition comprising, as an active ingredient, a peptide derived from the N terminus portion of αS1 casein and a pharmaceutically acceptable carrier.
A pharmaceutical composition for preventing or treating a bacterial infection the pharmaceutical composition comprising, as an active ingredient, a peptide derived from the N terminus portion of αS1 casein and a pharmaceutically acceptable carrier.
A method of low-temperature processing of casein proteolytic hydrolysate, the method comprising:
- a) obtaining a casein proteolytic hydrolysate comprising proteolytic enzymes;
- b) cooling said casein proteolytic hydrolysate so as to inactivate said proteolytic enzymes;
- c) adjusting the pH of said casein protein hydrolysate to an acid pH;
- d) filtering said acidic casein protein hydrolysate, collecting the filtrate, and further acidifying said filtrate so as to precipitate proteins derived from natural casein;
- e) separating and collecting said precipitate;
- f) adjusting the pH of said precipitate to an alkaline pH so as to irreversibly inactivate said proteolytic enzymes;
- and
- g) adjusting the pH of said precipitate to pH 7-9;
- thereby processing said casein protein hydrolysate at low temperature.
Dependencies are inferred from the claim text.